

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204063Orig1s000

**RISK ASSESSMENT and RISK MITIGATION
REVIEW(S)**

**Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology
Office of Medication Error Prevention and Risk Management**

Risk Management Review

Date: February 6, 2013

Reviewer(s): Kendra Worthy, Pharm. D., Team Leader, Division of Risk Management (DRISK)

Division Director: Mary Willy, Ph.D., Director (Acting), DRISK

Drug Name(s): Tecfidera (dimethyl fumarate) delayed release capsules, 120mg, 240mg

Indication(s): Treatment of patients with relapsing multiple sclerosis

Application Type/Number: NDA 204063

Applicant: Biogen Idec.

1 Introduction

This review documents the Division of Risk Management's (DRISK) evaluation of the need for a risk management strategy for dimethyl fumarate.

Biogen Idec submitted NDA 204063 for Tecfidera (dimethyl fumarate) with the proposed indication for relapsing forms of multiple sclerosis. The applicant did not propose a REMS or a risk management plan (RMP).

2 Background

Dimethyl fumarate is under consideration for the treatment of patients with relapsing forms of multiple sclerosis. It is dosed 120 mg orally twice daily for 7 days followed by a maintenance dose of 240 mg orally twice daily. The proposed label states (b) (4)

Dimethyl fumarate (as a combination product with monoethyl fumarate salts) is approved as Fumaderm in Germany for the treatment of psoriasis (1994).

3 Regulatory history

3.1 Product Labeling

The FDA-edited proposed labeling includes the following adverse reactions in the Warnings and Precautions section of the labeling.

- Lymphopenia and Risk of Infection
- Flushing

The label does not have a boxed warning.

4 Materials reviewed

4.1 Data Information Sources

- Midcycle review slides, Gerald Boehm, M.D., M.P.H. (safety), Medical Officers, Division of Neurology Products (DNP), dated January 9, 2013
- Draft clinical review (efficacy) by Heather Fitter, M.D., FACS, Medical Officers, DNP dated November 8, 2012.
- Clinical review (safety) by Gerald Boehm, M.D., M.P.H., Medical Officers, DNP dated January 9, 2013.
- Draft substantially complete label, Tecfidera (dimethyl fumarate), Biogen Idec, dated February 4, 2013.

5 Results of review

5.1 Overview of Clinical Program

Efficacy for the drug was established in two randomized, placebo-controlled trials with 2,665 exposed patients. One trial evaluated safety and efficacy of dimethyl fumarate 240 mg twice daily and 240 mg three times daily compared to placebo, and the second with an additional treatment arm of an “active comparator, Copaxone, in an open label rater blinded only fashion”¹. Primary endpoints included the proportion of patients relapsing at 2 years (first trial) and the annualized relapse rate (ARR) (second trial). Both trials included secondary endpoints related to MRI findings. The medical officer summarized that “both trials reported very robust findings on the primary clinical measures of relapse and were associated with p values of <0.0001 for all comparisons of active study treatment to placebo”¹, and that “all key secondary MRI endpoints for the active treatment vs. placebo comparisons in both trials were highly supportive (p<0.0001) of efficacy”.¹

Safety data was compiled from integrated data from 5 controlled trials with an MS arm (3) and psoriasis arm (2); each arm had open-label extension pools. The applicant also submitted postmarketing safety data for Fumaderm. Eleven deaths occurred; 9 in the treatment arm. Of those 9, seven occurred in the MS trials and 2 in the psoriasis trials. The integrated MS trials mortality was 0.3%, 1.6/1000 PY.²

5.2 Safety Concerns

Lymphopenia

In the MS placebo controlled trials, treated patients experienced a 30% mean decline from baseline in lymphocyte count, and the mean lymphocyte count remained reduced at 26% below baseline four weeks after discontinuation. The clinical safety reviewer states that the magnitude of the observed lymphocyte count decline with dimethyl fumarate is within the range of declines described for fingolimod and teriflunomide, two recently approved oral MS treatments.

Flushing

Flushing occurred in over 40% of treated patients. Flushing symptoms generally begin soon after initiating dimethyl fumarate and usually improve or resolve over time. Three percent (3%) of patients discontinued dimethyl fumarate for flushing and <1% had flushing symptoms that were serious. The label states that administration of dimethyl fumarate with food may reduce the incidence of flushing.

Renal toxicity

Kidney changes (tubular and interstitial toxicity) were observed in the preclinical trials in multiple species; however there was no evidence of an increased risk to patients in the

¹ Draft clinical review (efficacy) by Heather Fitter, M.D., FACS, Medical Officers, DNP dated November 8, 2012.

² Midcycle review slides, Gerard Joehm, M.D., M.P.H., Medical Officer, DNP, dated January 9, 2013.

clinical trials. The applicant states that they intend to monitor this potential risk in the post marketing setting with targeted follow-up of cases suggestive of renal toxicity³.

Malignancy

Dr. Boehm states in his review that the review team “became aware of publications that identified a metabolite of dimethyl fumarate, fumarate, as an ‘oncometabolite’”, so the Agency extended the PDUFA goal date to examine additional data from the sponsor regarding this metabolite. He goes on to state:

“The medical literature explains that mutations resulting in significant declines or loss of fumarate hydratase (FH) function result in increased intracellular levels of fumarate. Increased intracellular levels of fumarate are presumed to be responsible for the sequelae of leiomyomata and renal cell cancers seen in the Hereditary Leiomyoma and Renal Cell Cancer (HLRCC) syndrome.

We lack information to determine if ingesting [dimethyl fumarate] results in increased intracellular levels of fumarate. Fumarate was not detected in plasma levels of patients administered DMF, but this does not necessarily preclude the possibility of increased intracellular fumarate levels.

The available NDA data do not suggest that treatment with [dimethyl fumarate] results in the outcomes seen with reduced FH function. While this difference may be because treatment with [dimethyl fumarate] does not result in the increased intracellular fumarate levels seen with FH deficiency, as Biogen proposes, we do not currently have data to confirm this hypothesis.”³

Dr. Boehm also recommended that the applicant monitor post marketing reports to identify cases of leiomyomata and or renal cell cancers in patients treated with dimethyl fumarate.

Elevated Liver Enzymes

Elevated hepatic transaminases were observed in the treatment (4%) and placebo (2%) groups in clinical trials, with the majority of the elevations being < 3 times the upper limit of normal (ULN). The increased incidence of elevations of hepatic transaminases in patients treated with dimethyl fumarate relative to placebo was primarily seen during the first six months of treatment and occurred at levels < 3 times the ULN. Discontinuations due to elevations in hepatic transaminases were < 1% and were similar in both the treatment and placebo groups.⁴

³ Clinical review (safety) by Gerald Boehm, M.D., M.P.H., Medical Officers, DNP dated January 9, 2013.

⁴ Draft substantially complete label, Tecfidera (dimethyl fumarate), Biogen Idec.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.